--- title: "Insmed (INSM) stock news, pipeline, cash and catalysts" url: "https://aibio.space/companies/insmed/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Insmed news for investors: Insmed sells Brinsupri for bronchiectasis and Arikayce for MAC lung disease, and is developing TPIP, an inhaled once-daily…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Insmed's launch is working. TPIP is the next test Insmed has turned Brinsupri into a fast launch and is close to breakeven, with management targeting positive cash flow in 2027. The next leg depends on TPIP's phase 3 trials and on a clean CFO handover. Read the full desk view aibio.space Investor Rank · Opinion **8** /10 Positive view Brinsupri is a fast launch and losses have nearly closed, with about $1.2 billion of cash; the next leg depends on TPIP phase 3 trials. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Commercially proven.** Brinsupri sold $309.2 million in Q2 2026, and TPIP held gains at 12 months in an open-label PAH study. - **Odds**: **Phase 3 base rates apply.** TPIP is in phase 3, where about 52% of programs historically reach approval. - **Balance sheet**: **Near breakeven.** About $1.2 billion in cash and securities, $543.5 million in debt, and a Q2 loss of only $13.2 million. - **Main risk**: **Brinsupri concentration.** One drug drives growth, almost all of it in the U.S., while the CFO seat is open. - **Watch next**: **October 29 results.** The first report since the CFO exit will show whether Brinsupri kept its second-quarter pace. ## Top news on Insmed ## Dates **October 29, 2026** Third-quarter 2026 results and call [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_ex99-1.htm) **2H 2026** Japanese regulatory decision on brensocatib in bronchiectasis [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) **2H 2026** Arikayce sNDA submission for all MAC lung disease patients, based on ENCORE [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_ex99-1.htm) **2H 2026** Start of TPIP phase 3 in progressive pulmonary fibrosis [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) **1H 2027** Start of TPIP phase 3 in idiopathic pulmonary fibrosis [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) ## The money About $1.2 billion in cash, cash equivalents and marketable securities at June 30, 2026 (Q2), with $543.5 million in long-term debt. Insmed says it has enough money for at least 12 months and expects positive cash flow in 2027. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) Q2 2026 total revenue $425.5 million, up 296%: Brinsupri $309.2 million, Arikayce $116.3 million. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) ## Risks on the record - The phase 2b CEDAR trial of brensocatib in hidradenitis suppurativa missed its primary and secondary endpoints in April 2026, and Insmed ended the program. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/ef20070042_ex99-1.htm) - Four wholesale customers accounted for 92% of gross product revenue in the first half of 2026. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) - Chief financial officer Sara Bonstein leaves after October 30, 2026, and a successor has not been named. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_ex99-1.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for Insmed? 8 out of 10, our positive view. Brinsupri is a fast launch and losses have nearly closed, with about $1.2 billion of cash; the next leg depends on TPIP phase 3 trials. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### How much did Brinsupri sell in Q2 2026? Brinsupri sold $309.2 million in the second quarter of 2026, up 49% from the first quarter. Almost all of it, $308.6 million, came from the U.S. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) ### What is Insmed's 2026 revenue guidance? Insmed expects $1.25 billion to $1.40 billion in Brinsupri sales and $450 million to $470 million in Arikayce sales for 2026. It reaffirmed both ranges on October 5, 2026. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_ex99-1.htm) ### Why is Insmed's CFO leaving? Sara Bonstein said she wants to pursue a broader leadership role. Insmed said her departure is not due to any disagreement over accounting, financial statements, internal controls or operations, and she stays through October 30, 2026. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_ex99-1.htm) ### When does Insmed report Q3 2026 earnings? Insmed plans to report third-quarter 2026 results on October 29, 2026, with a conference call at 8:00 a.m. ET. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_ex99-1.htm) ### What is TPIP and what stage is it in? TPIP is treprostinil palmitil inhalation powder, a once-daily inhaled treatment Insmed is testing in pulmonary arterial hypertension and pulmonary hypertension tied to interstitial lung disease. It is in phase 3 in both, and Insmed estimates peak sales above $6 billion. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) ### What is Insmed's market cap? We do not publish live share prices. In its annual report, Insmed Incorporated put the market value of shares held by non-affiliates (public float) at $21.10 billion as of Jun 30, 2025. Source ### Is Insmed a smaller reporting company? SEC records list Insmed Incorporated's filer category as: Large accelerated filer. Source ### Where is Insmed headquartered? SEC records list its business address as 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807. Source ### When does Insmed's fiscal year end? Insmed Incorporated's fiscal year ends on December 31, per SEC records. Source ### What did Insmed last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-10-20. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/ef20084030_8k.htm) ### What industry is Insmed in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ## Legal and investor matters Checked against Insmed filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Insmed's 10-Q filed 2026-08-06 (Note 15, Legal Proceedings) says Insmed is from time to time a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business, and that management does not expect the ultimate costs to resolve them to have a material adverse effect on its financial position, results of operations or cash flows. [Source](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) 1. 2026-10-20 Governance Insmed adds former Sanofi CEO Paul Hudson and Utpal Koppikar to board Insmed said in an 8-K filed 2026-10-20 that its board appointed Paul Hudson and Utpal Koppikar as directors effective 2026-10-19. Hudson, a Class II director, joins the compensation committee. Koppikar, a Class I director, joins the audit committee. Both stand for election at the 2027 annual meeting. The filing says Hudson was Sanofi chief executive from September 2019 through February 2026. [Insmed Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/ef20084030_8k.htm) 2. 2026-10-05 Governance Insmed says chief financial officer Sara Bonstein will leave on 2026-10-30 Insmed disclosed on 2026-10-05 that chief financial officer Sara Bonstein would separate from the company effective 2026-10-30, and that a search for a successor is underway. The 8-K says the separation is not related to any disagreement over accounting practices, financial statements, internal controls or operations. [Insmed Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_8k.htm) 3. 2026-05-15 Governance Insmed annual meeting: directors elected, pay vote passes, auditor ratified Insmed reported on 2026-05-15 the results of its 2026-05-13 annual meeting. Shareholders elected Elizabeth McKee Anderson and Clarissa Desjardins as Class II directors. The advisory vote on 2025 executive pay had 162,133,728 votes for and 23,657,325 against. Shareholders ratified Ernst & Young LLP as auditor for 2026. [Insmed Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126021648/ef20073378_8k.htm) 4. 2025-06-13 Financing Insmed sells 7.8 million shares in underwritten offering, net about $716 million Insmed entered into an underwriting agreement on 2025-06-11 with Goldman Sachs and Leerink Partners to sell 7,812,500 common shares, with a 30-day option for 1,171,875 more. The underwriters bought the firm shares at $91.68 per share after discounts, for net proceeds to Insmed of about $716.3 million before other expenses. The offering used its automatic shelf registration. [Insmed Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/ny20050461x3_8k.htm) 5. 2024-11-19 Financing Insmed terminates $500 million at-the-market sales agreement with Leerink Insmed disclosed on 2024-11-19 that it terminated, effective 2024-11-18, its 2024-02-22 sales agreement with Leerink Partners that allowed sales of up to $500 million of common stock. The company said no shares had been sold under it since 2024-09-30 and that it owed no termination penalties. [Insmed Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036124047246/ef20038832_8k.htm) 6. 2024-10-31 Financing Insmed adds $150 million term loan tranche and extends Pharmakon loan to 2029 On 2024-10-31 Insmed amended and restated its loan agreement with funds managed by Pharmakon Advisors. The amendment adds a new $150 million senior secured Tranche B term loan next to the existing $350 million Tranche A. The filing says the term loans bear a fixed 9.60% rate and mature 2029-09-30, subject to acceleration. [Insmed Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/ef20037942_8k.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Brinsupri (brensocatib) | Non-cystic fibrosis bronchiectasis, Japan | Regulatory decision expected 2H 2026 [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) | | Arikayce | All patients with MAC lung disease | Phase 3b ENCORE positive, sNDA planned 2H 2026 [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_ex99-1.htm) | | TPIP (treprostinil palmitil inhalation powder) | Pulmonary arterial hypertension | Phase 3 PALM-PAH enrolling [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) | | TPIP | Pulmonary hypertension with interstitial lung disease | Phase 3 PALM-ILD enrolling [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) | | TPIP | Progressive pulmonary fibrosis | Phase 3 start planned 2H 2026 [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) | | INS1033 | Rheumatoid arthritis | IND cleared July 2026, phase 1 in healthy volunteers [Source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) | Opinion · Devil's advocate ## Fact-check-o-meter Consistent Insmed's messaging tracks its 10-Q, but the inhaled PAH drug story leans on uncontrolled data The second-quarter release and the 10-Q agree on cash, revenue and the absence of any material litigation. The cautious points are on the science: the 12-month TPIP update comes from an open-label extension with no control arm, and the peak sales estimates in the release do not appear in the 10-Q. 1. Science · weight medium TPIP "safe and well-tolerated" headline sits on an uncontrolled extension study **The company said:** "TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12" [source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_ex99-1.htm) **The record says:** The same release states "The OLE study is a non-placebo-controlled trial," and its safety paragraph adds: "Of the 91 patients in the study, treatment-emergent adverse events (TEAEs) occurred in 89.0% of patients; serious TEAEs were observed in 18.7% of patients." It also reports four deaths, "none of which were considered related to TPIP treatment," and discontinuations for TEAEs in 7.7% of patients. ClinicalTrials.gov lists the extension (NCT05649748) as unmasked with a safety primary outcome, so the walk-distance and NT-proBNP gains are not primary endpoints. [source](https://clinicaltrials.gov/study/NCT05649748) **Our view:** Sustained gains in an open-label group of 91 patients are encouraging but cannot separate drug effect from patient selection or expectation. The adverse event rates are typical of a sick PAH population, and the release discloses them, but "safe and well-tolerated" is the company's reading. The placebo-controlled Phase 3 PALM-PAH is the real test. 2. Science · weight medium Phase 2b win was on a hemodynamic measure, not how patients function **The company said:** "the statistically significant and clinically meaningful results from our Phase 2b randomized study" [source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_ex99-1.htm) **The record says:** ClinicalTrials.gov lists the randomized, double-masked Phase 2 study (NCT05147805) with 102 participants and a single primary outcome: "Change from Baseline in Pulmonary Vascular Resistance at Week 16." The 10-Q says the Phase 3 PALM-PAH study began in April 2026 and is still enrolling. [source](https://clinicaltrials.gov/study/NCT05147805) **Our view:** Pulmonary vascular resistance is an accepted early-phase measure in PAH, but it is a surrogate. Phase 3 will need to show benefit on outcomes such as walk distance or clinical worsening. 3. Press release vs filing · weight medium Peak sales targets appear in the release, not in the 10-Q **The company said:** "We now expect that our three lead programs will generate more than $14 billion in combined peak sales." [source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) **The record says:** The 10-Q does not repeat any peak revenue estimate. It describes TPIP as in Phase 3 (PALM-ILD enrolling, PALM-PAH enrolling, a progressive pulmonary fibrosis study planned for the second half of 2026) and reports an accumulated deficit of $5.8 billion. The release's own forward-looking section lists "inaccuracies in our peak sales estimates for our marketed products and our product candidates" among its risks. [source](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) **Our view:** Peak sales figures are company opinion, and the release says so in its caution language. A more-than-$6 billion TPIP figure applies to a drug with no Phase 3 data yet, so it reads as a company goal, not a forecast. 4. Press release vs filing · weight low Small quarterly loss versus a $176.8 million six-month loss **The company said:** "For the second quarter of 2026, Insmed reported a net loss of $13.2 million, or $0.06 per share, compared to a net loss of $321.7 million, or $1.70 per share, for the second quarter of 2025." [source](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) **The record says:** The 10-Q confirms the $13,242 thousand quarterly loss and reports a six-month net loss of $176,805 thousand. Management states: "we anticipate that our cash and cash equivalents and marketable securities as of June 30, 2026 will enable us to fund our operations for at least the next 12 months." The filing carries no going-concern doubt language. [source](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) **Our view:** The release numbers are accurate and the quarter was near break-even. The first quarter was much weaker, and the funding statement in the 10-Q is a 12-month one. One quarter is a data point rather than a trend. 5. Legal and disclosure record · weight low No material litigation disclosed **The record says:** The 10-Q Legal Proceedings note states: "From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect." No securities litigation or enforcement disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) **Our view:** The record is clean in the filing we read. Arikayce's US label is still an accelerated approval, which the 10-Q notes, so the sNDA submitted in July is a regulatory item to follow. Documents we compared - [Insmed Q2 2026 results press release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm) 2026-08-06 - [Insmed Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) 2026-08-06 - [Insmed TPIP 12-month OLE data press release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_ex99-1.htm) 2026-07-16 - [ClinicalTrials.gov NCT05649748 (TPIP extension study)](https://clinicaltrials.gov/study/NCT05649748) 2026-10-23 - [ClinicalTrials.gov NCT05147805 (TPIP phase 2 PAH)](https://clinicaltrials.gov/study/NCT05147805) 2026-10-23 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INSM on TradingView](https://www.tradingview.com/symbols/NASDAQ-INSM/). ## SEC filings and registration - **SEC name**: INSMED Inc - **CIK**: 1104506 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: INSM (Nasdaq) - **State or country of incorporation**: VA - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807 - **Phone**: 908-977-9900 - **Shares outstanding**: 218,381,503 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/ef20084030_8k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_8k.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_8k.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_8k.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126021648/ef20073378_8k.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_8k.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000032/insm-20260331.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001104506), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/insmed/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Insmed (INSM) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/insmed/